Evidence map›Paper›PMID 27431653›Full record

ArticleBMC cancer2016

New anti-cancer chemicals Ertredin and its derivatives, regulate oxidative phosphorylation and glycolysis and suppress sphere formation in vitro and tumor growth in EGFRvIII-transformed cells.

Sonoko Atsumi, Chisato Nosaka, Hayamitsu Adachi, Tomoyuki Kimura, Yoshihiko Kobayashi, Hisashi Takada, Takumi Watanabe, Shun-Ichi Ohba, Hiroyuki Inoue, Manabu Kawada and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Sonoko AtsumiLaboratory of Oncology, Institute of Microbial Chemistry, 3-14-23 Kamiosaki, Shinagawa-ku, 141-0021, Tokyo, Japan. atsumi@bikaken.or.jp.
Chisato NosakaLaboratory of Oncology, Institute of Microbial Chemistry, 3-14-23 Kamiosaki, Shinagawa-ku, 141-0021, Tokyo, Japan.
Hayamitsu AdachiNumazu Branch, Institute of Microbial Chemistry, Miyamoto, Numazu-shi, Shizuoka, Japan.
Tomoyuki KimuraLaboratory of Synthetic Organic Chemistry, Institute of Microbial Chemistry, Kamiosaki, Shinagawa-ku, Tokyo, Japan.
Yoshihiko KobayashiLaboratory of Synthetic Organic Chemistry, Institute of Microbial Chemistry, Kamiosaki, Shinagawa-ku, Tokyo, Japan.
Hisashi TakadaLaboratory of Synthetic Organic Chemistry, Institute of Microbial Chemistry, Kamiosaki, Shinagawa-ku, Tokyo, Japan.
Takumi WatanabeLaboratory of Synthetic Organic Chemistry, Institute of Microbial Chemistry, Kamiosaki, Shinagawa-ku, Tokyo, Japan.
Shun-Ichi OhbaNumazu Branch, Institute of Microbial Chemistry, Miyamoto, Numazu-shi, Shizuoka, Japan.
Hiroyuki InoueNumazu Branch, Institute of Microbial Chemistry, Miyamoto, Numazu-shi, Shizuoka, Japan.
Manabu KawadaLaboratory of Oncology, Institute of Microbial Chemistry, 3-14-23 Kamiosaki, Shinagawa-ku, 141-0021, Tokyo, Japan.
Masakatsu ShibasakiLaboratory of Oncology, Institute of Microbial Chemistry, 3-14-23 Kamiosaki, Shinagawa-ku, 141-0021, Tokyo, Japan.
Masabumi ShibuyaInstitute of Physiology and Medicine, Jobu University, Takasaki-shi, Gunma, Japan.
Microbial Chemistry Research Foundation · JPJobu University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEGFRvIII is a mutant form of the epidermal growth factor receptor gene (EGFR) that lacks exons 2-7. The resulting protein does not bind to ligands and is constitutively activated. The expression of EGFRvIII is likely confined to various types of cancer, particularly glioblastomas. Although an anti-EGFRvIII vaccine is of great interest, low-molecular-weight substances are needed to obtain better therapeutic efficacy. Thus, the purpose of this study is to identify low molecular weight substances that can suppress EGFRvIII-dependent transformation.

methodsWe constructed a new throughput screening system and searched for substances that decreased cell survival of NIH3T3/EGFRvIII spheres under 3-dimensional (3D)-culture conditions, but retained normal NIH3T3 cell growth under 2D-culture conditions. In vivo activity was examined using a mouse transplantation model, and derivatives were chemically synthesized. Functional characterization of the candidate molecules was investigated using an EGFR kinase assay, immunoprecipitation, western blotting, microarray analysis, quantitative polymerase chain reaction analysis, and measurement of lactate and ATP synthesis.

resultsIn the course of screening 30,000 substances, a reagent, "Ertredin" was found to inhibit anchorage-independent 3D growth of sphere-forming cells transfected with EGFRvIII cDNA. Ertredin also inhibited sphere formation in cells expressing wild-type EGFR in the presence of EGF. However, it did not affect anchorage-dependent 2D growth of parental NIH3T3 cells. The 3D-growth-inhibitory activity of some derivatives, including those with new structures, was similar to Ertredin. Furthermore, we demonstrated that Ertredin suppressed tumor growth in an allograft transplantation mouse model injected with EGFRvIII- or wild-type EGFR-expressing cells; a clear toxicity to host animals was not observed. Functional characterization of Ertredin in cells expressing EGFRvIII indicated that it stimulated EGFRvIII ubiquitination, suppressed both oxidative phosphorylation and glycolysis under 3D conditions, and promoted cell apoptosis.

conclusionWe developed a high throughput screening method based on anchorage-independent sphere formation induced by EGFRvIII-dependent transformation. In the course of screening, we identified Ertredin, which inhibited anchorage-independent 3D growth and tumor formation in nude mice. Functional analysis suggests that Ertredin suppresses both mitochondrial oxidative phosphorylation and cytosolic glycolysis in addition to promoting EGFRvIII degradation, and stimulates apoptosis in sphere-forming, EGFRvIII-overexpressing cells.

Indexed as

AnimalsAntineoplastic AgentsApoptosisBlotting, WesternCell Culture TechniquesCell Transformation, NeoplasticErbB ReceptorsGene Expression Regulation, NeoplasticGlycolysisHumansMiceMice, Inbred BALB CMice, NudeMolecular StructureNIH 3T3 CellsOxidative PhosphorylationAntineoplastic Agentsepidermal growth factor receptor VIIIErbB ReceptorsertredinQuinoxalines3DAnchorage-independentApoptosisEGFRvIIIErtredinGlycolysisOxidative phosphorylationSphere

Identifiers

PMID27431653
PMCPMC4949881
OpenAlexW2504612005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.